All News

Krazati’s benefits were seen regardless of baseline brain metastases, researchers have reported in findings from the KRYSTAL-12 trial.

An expert provides answers to pressing questions regarding different aspects of a kidney cancer journey, including stage, grade and treatment options.

Two vastly different approaches to navigating the cancer journey may or may not be mutually exclusive.

An expert discussed the findings of the COMMANDS trial evaluating Reblozyl’s role in red blood cell transfusion independence for patients with MDS.

Among patients with limited-stage small cell lung cancer, the benefits of consolidation Imfinzi were seen across a number of subgroups.

Adding Nubeqa to androgen deprivation therapy improved radiographic progression-free survival in patients with metastatic hormone-sensitive prostate cancer.

CAR-T cell therapies administered in an outpatient setting may be safe and feasible without intensive remote monitoring in hematologic malignancies.

Recently, I met a fellow cancer survivor but after talking with her about cancer, I realized she had a different perspective than I did.

Steatotic liver disease was associated with better liver function, lower recurrence rates, and improved overall survival in patients with liver cancer who received radiofrequency ablation.

Enhertu improved the time it took for patients with a breast cancer subset to experience worsening pain and other symptoms, without affecting overall quality of life.

A recent study compared two dosages of ifinatamab deruxtecan among patients with extensive-stage small cell lung cancer.

When my daughter couldn't express her words while she received treatment for brain cancer, her eyes told me everything I needed to know.

At the 2024 ESMO Congress, CURE® spoke with an expert about Fotivda and certain challenges patients may experience, such as side effects.

The Food and Drug Administration has approved Sarclisa as a first-line treatment for patients with multiple myeloma who are ineligible for autologous stem cell transplant.

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived without signs of cancer.

With my myelodysplastic syndrome and age, I find it hard to keep up; however, cancer and fatigue have taught me to live at my own pace.

From model Bianca Balti’s ovarian cancer diagnosis to hockey pro’s testicular cancer diagnosis, here’s what’s happening in the oncology space this week.

The 12-month survival rates in patients with non-clear cell renal cell carcinoma showed improvements after treatment with Yervoy plus Opdivo.

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.

The FDA has approved Rybrevant plus chemotherapy in certain patients with locally advanced or metastatic non-small cell lung cancer.

First-time treatment with Lenvima continues to outperform other treatments for thyroid cancer.

Through communication and education, patients with metastatic breast cancer may be able to balance treatment with quality of life.

I bought 14 precious cancer bracelets in a discount store to help spread awareness about cancer — something I’m ready to speak out about.

While infections pose a risk for morbidity and mortality among patients with MDS, more needs to be studied about the topic, researchers urged.

In patients with BRAF V600E-mutant metastatic colorectal cancer, a combination of Braftovi, Erbitux and chemotherapy showed promising antitumor activity.

Although Jakafi has been approved for patients with higher-risk myelofibrosis, those with lower-risk disease may also benefit from this treatment.

An expert explained the burden that red blood cell transfusions can place on patients with MDS.

The past 15 months have been challenging regarding treatment for my ovarian cancer. But today, my goal is to focus on healing my mind, body and soul.

Trodelvy in locally advanced or metastatic urothelial cancer may provide another option for those whose disease progressed after checkpoint inhibitors.

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset.